Durvalumab + tremelimumab + enfortumab vedotin vs standard of care, perioperative cisplatin-ineligible muscle-invasive bladder cancer.
The VOLGA trial reports out this month. Below are the headline numbers Encounter predicted before any results were public. Each row is a falsifiable claim with a value range.
| Metric | Predicted value |
|---|---|
| pCR triplet arm (durva + treme + EV) | ~40.6% |
| pCR duplet arm (durva + EV) | Lower than triplet |
| pCR control (chemo / SOC) | ~25–30% |
| Δ triplet vs control | ~10–15 percentage points |
| ctDNA clearance, triplet arm | ≥70% |
| PD-L1 negative subgroup | Still responds well |
The critical test: if Arm A > Arm B > Control, the benefit scales with the number of independent steps the regimen covers. That pattern in one data table is the structural prediction in its falsifiable form.
AstraZeneca reported a safety run-in of the VOLGA triplet at ESMO 2024 with pathological complete response in 6 of 17 evaluable patients — 35%. That is not the primary analysis, the sample is small, and a run-in is not powered for an efficacy read. It is directionally consistent with the framework's 40.6% point prediction and sits well below the ≥50% figure v1 and v2 of this scorecard published. v3 corrects the number.
The structural reasoning behind the call — which steps in the immune cycle each drug covers, why three steps differ from two, where the prediction would break, what it means for the design of follow-on trials in adjacent indications — is in the full report. The full report also includes the framework's per-metric reasoning for each row in the table above, the structural mapping for the trial's three arms, and the implications for a sponsor running a similar combination in a different indication.
Fill the form to start the purchase. We reply within two business days with the price, scope, and a Stripe invoice. The full report is delivered as a PDF on payment.
* Trial cost estimate: 677 patients × $40K median per patient (oncology Phase 3, US sites, Moore et al. 2018 cross-sectional analysis of 2015–2017 trials). Order-of-magnitude only — actual VOLGA cost is not publicly disclosed.